Table 2.
Features of renal injuries in some rat and mouse models of type 2 DN.
| Model | Type 2 | Description | Features of renal injury | Ref. |
|---|---|---|---|---|
| Genetically | Goto-Kakizaki (GK) | GK rat has a decreased β-cell mass and insulin resistance | ☑ Glomerular hypertrophy and GBM thickening, segmental glomerulosclerosis, and tubulointerstitial fibrosis, relatively resistant to the development DN | [83–85] |
| (Otsuka Long-Evans Tokushima Fatty rat) OLETF | Deficiency of CCK-A receptor in the pancreas | ☑ Hypertension, glomerular hypertrophy, GBM thickening, extracellular matrix expansion, nodular lesions, diffuse glomerulosclerosis, and severe tubulointerstitial fibrosis and macroalbuminuria, glomerulosclerosis in these models appears in older rats, mild obesity, late-onset hyperglycemia | [79] | |
| Zucker diabetic fatty rats (ZDF) | Obese Zucker fa/fa rats×Wistar Kyoto rats, possess leptin-receptor mutation | ☑ Heavy proteinuria and glomerulosclerosis tubulointerstitial and vascular damage | [80, 81] | |
| ZSF1 | ZDF×SHHF | ☑ Massive proteinuria, glomerulosclerosis, severe tubulointerstitial, vascular damage, and reduced GFR | ||
| Ob/ob mice | Ob/ob mutation (a recessive mutation in the gene coding leptin), they are developed through β-cell atrophy and severe hyperglycemia | ☑ Destruction of podocytes, proteinuria and diffuse and nodular lipohyaline | [86–90] | |
| Db/db mice | Mutations in the leptin receptor (similar to the Zucker rat) | ☑ Glomerular hypertrophy, mesangial matrix expansion, GBM thickening do not develop advanced human DN (mesangiolysis or widespread marked or nodular mesangial sclerosis) | [92–94] | |
| MKR mice | Lack insulin-like growth factor 1 receptor | ☑ Increased GFR, exhibit significant albuminuria nephropathy be exacerbated by uninephrectomy or high-fat diet | [102] | |
| Tsumura Suzuki Obese Diabetes mouse (TSOD) | Selective breeding of obese ddy strain with spontaneous DM | ☑ Thickening of the glomerular basement membrane and mesangial area expansion were observed | [103, 104] | |
| KK mice | Is a hyperinsulinemic model that only displays mild renal pathology | ☒Needs prolonged periods to develop diabetes and does not develop advanced DN | [23, 105] | |
| KKAy mice | KK mice×yellow obese Ay | ☑ Significant elevation of albuminuria becomes progressively greater during diabetes progress | [106, 107] | |
| KKAy/Ta mice | Produced by transfection of the yellow obese gene (Ay) into KK/Ta mice | ☑ Extracellular mesangial matrix and proliferative glomerular nephritis with expansion of glomerular | [109, 110] | |
| NZO (new Zealand obese mouse) | This mice has a polygenetically inherited form of diabetes | ☑ Displays progressive renal pathological features as evidenced by GBM thickness and diffuse and nodular expansion of the mesangial matrix | [98] | |
|
| ||||
| Chemical | STZ-nicotinamide | STZ (45 to 65 mg/kg)+NA (60 to 290 mg/k) were used, NA must be injected 15 min before the administration of STZ | ☑ Glomerular hypertrophy, leukocyte infiltration, and glomerulosclerosis | [34, 111, 112] |
| Neonatal STZ | Injection of single dose of STZ at the dose range of 80-100 mg/kg to neonatal rats (2-5 day old) leads to induction of type 2 diabetes in adult ages | ☑ Albuminuria, enhanced kidney index, and pathological changes | [114, 115] | |
|
| ||||
| Chemical+diet | Fat-fed STZ rat | Following 2-4 weeks of dietary intervention 60% fat diet+35 mg/kg STZ | ☑ Renal injury including increasing albuminuria, kidney index, and pathological changes | [126–128] |
|
| ||||
| Surgical+chemical+diet | High-fat diet in low-dose-STZ-treated, heminephrectomized | Heminephrectomy performed following injection STZ (25-40 mg/kg)+feeding these rats with high-fat chow (40-58% calories as fat) | ☑ Overt proteinuria, mesangial matrix proliferation, and interstitial edema | [130–132] |
|
| ||||
| Diet | Fructose-fed rats | Administrated of fructose in drinking water (10% or 20% W/V) or as 60% diet | ☑ Either in drinking water or diet administration is associated with renal disorder characterized by arteriolopathy, renal hypertrophy, and glomerular hypertension | [78, 119] |